Serotonin News and Research

Latest Serotonin News and Research

New research may help unravel cellular brain activity involved in human decisions

Crayfish make surprisingly complex, cost-benefit calculations, finds a University of Maryland study, opening the door to a new line of research that may help unravel the cellular brain activity involved in human decisions.

16 Jun 2010

Research may lead to better treatments for depression and substance abuse

In what has been hailed as a breakthrough, scientists from Columbia University Medical Center and Weill Cornell Medical College have outlined the molecular mechanism of membrane transport. The research shows how a protein transforms its shape to transport substances across the cell membrane in order to regulate transmission of the brain's messages across the synaptic gap from one neuron to another.

11 Jun 2010

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.

9 Jun 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

University of Michigan scientists have provided the most detailed picture yet of a key receptor in the brain that influences the effectiveness of serotonin-related antidepressants, such as Prozac.

1 Jun 2010

New study finds usage of antidepressants increases risk of miscarriage in pregnant women

A new study in CMAJ (Canadian Medical Association Journal) found a 68% increase in the overall risk of miscarriage in pregnant women using antidepressants.

1 Jun 2010

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Researchers in the University of Alberta's Faculty of Rehabilitation Medicine have made an important discovery that could lead to more effective treatments for spinal-cord injuries. Karim Fouad and David Bennett have identified one of the body's natural self-repair mechanisms that kick in after injury.

31 May 2010

Combination therapy improves patients with depression symptoms: Study

New data presented today at the American Psychiatric Association's annual meeting suggests a benefit to combining L-methylfolate, a prescription medical food called Deplin, with an antidepressant at the start of treatment. This retrospective analysis showed a significantly greater improvement in depression symptoms in a shorter period of time, when patients with Major Depressive Disorder were started on combination therapy.

25 May 2010

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for vilazodone for the treatment of major depressive disorder.

24 May 2010

Study confirms low levels of serotonin transporter in cerebral cortex of chronic ecstasy users

Levels of the serotonin transporter are low in the brains of users of ecstasy, according to a US National Institute of Drug Abuse-funded study by Toronto's Centre for Addiction and Mental Health (CAMH) and The Hospital for Sick Children (SickKids) published today in the journal Brain.

19 May 2010

Combining medicine switch with cognitive behavioral therapy can reduce symptoms of depression: Study

More than one-third of teenagers with treatment-resistant depression - many of whom had been depressed for more than two years - became symptom-free six months after switching their medication or combining a medicine switch with cognitive behavioral therapy during a multicenter study led by UT Southwestern Medical Center researchers.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.

13 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Labopharm Inc. today reported its financial results for the first quarter 2010.

6 May 2010

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome at Digestive Disease Week 2010 in New Orleans, Louisiana.

6 May 2010

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

Most people associate serotonin with brain neurology, but over 95 percent of the body's serotonin occurs in the gastrointestinal tract, which has a complex neuronal circuit that has been called "the second brain" of the body.

5 May 2010

Serotonin News and Research

Latest Serotonin News and Research

New research may help unravel cellular brain activity involved in human decisions

Research may lead to better treatments for depression and substance abuse

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

New study finds usage of antidepressants increases risk of miscarriage in pregnant women

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Combination therapy improves patients with depression symptoms: Study

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Study confirms low levels of serotonin transporter in cerebral cortex of chronic ecstasy users

Combining medicine switch with cognitive behavioral therapy can reduce symptoms of depression: Study

152 research and training grants awarded to researchers at 93 institutions nationwide

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Lexicon Pharmaceuticals first-quarter revenues down 61%

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Serotonin News and Research

Latest Serotonin News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in